In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
All content for B Heppy is the property of Hepatitis B Foundation and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
Why the First Shot Matters: Confronting Hepatitis B Birth Dose Hesitancy
B Heppy
41 minutes
3 months ago
Why the First Shot Matters: Confronting Hepatitis B Birth Dose Hesitancy
In this episode, Bright and Anousha invited Dr. David Higgins, a pediatrician and leading expert in vaccine delivery and communication from University of Colorado Anschutz Medical Campus. He sheds light on common myths and misconceptions about the hepatitis B birth dose and offers practical strategies for healthcare providers and advocates to address concerns with parents using empathy and evidence-based science. Support the show Our website: www.hepb.org Support B Heppy! Social Media: Instag...
B Heppy
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
